Press Releases

Branca Bunús are delighted to announce they have closed a sub-licensing agreement, granting to Branca Bunús rights to use key patents for the production and marketing of a novel gene editing platform technology. Gene editing is an attractive alternative to classical gene therapy, in that its basis is the fundamental editing and correction of mutant genes that give rise to a host of inherited disorders. The patent holders- University College Dublin, in association with the scientific inventors at the UCD Charles Institute of Dermatology, reached an agreement to grant a sub-licence in this technology to address a rapidly growing demand within the pharmaceutical sector to develop alternative non-viral delivery vectors for treating genetic disorders. Branca bunús having been encouraged on the back of preliminary data showing that the treatment could be disease modifying for patients suffering with an orphan skin disorder known as Recessive Dystrophic Epidermolysis Bullosa (RDEB).

“This is a fantastic opportunity for Branca Bunús to position ourselves within the gene editing landscape, a truly disruptive and transformative medical area in todays world” said  company CEO Dr. Hongyun Tai. “This technology gives us platform applicability with our initial focus on the development of a treatment for RDEB, that is virus free and offers considerable benefits over conventional gene replacement strategies. If successful , going forward this platform technology can be adapted to target alternative genetic disorders.”

For more information on Branca Bunús, please contact us at www.brancabunus.com or via email at [email protected]